Compare · CUPR vs NVO
CUPR vs NVO
Side-by-side comparison of Cuprina Holdings (Cayman) Limited (CUPR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CUPR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 24150.2x CUPR ($8.9M).
- Over the past year, CUPR is down 94.3% and NVO is down 29.3% - NVO leads by 65.0 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for CUPR).
- NVO has more recent analyst coverage (25 ratings vs 0 for CUPR).
- Company
- Cuprina Holdings (Cayman) Limited
- Novo Nordisk A/S
- Price
- $3.56-7.77%
- $48.78+1.22%
- Market cap
- $8.9M
- $215.95B
- 1M return
- -38.19%
- +2.89%
- 1Y return
- -94.27%
- -29.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 1
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CUPR
- SEC Form F-1 filed by Cuprina Holdings (Cayman) Limited
- Amendment: SEC Form 20-F/A filed by Cuprina Holdings (Cayman) Limited
- SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited
- Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product
- SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited
- Cuprina Holdings (Cayman) Limited Regains Compliance with Nasdaq Listing Requirements
- Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing
- Cuprina Holdings announces 1-for-8 Share Consolidation
- SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited
- Amendment: SEC Form 6-K/A filed by Cuprina Holdings (Cayman) Limited
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S